LifeVantage (NASDAQ:LFVN) Earns Buy Rating from Analysts at Lake Street Capital

Investment analysts at Lake Street Capital initiated coverage on shares of LifeVantage (NASDAQ:LFVN) in a research note issued on Thursday,Benzinga reports. The brokerage set a “buy” rating and a $26.00 price target on the stock. Lake Street Capital’s price target would indicate a potential upside of 69.38% from the stock’s previous close.

LifeVantage Trading Down 7.5 %

Shares of NASDAQ LFVN opened at $15.35 on Thursday. The firm has a fifty day simple moving average of $13.77 and a two-hundred day simple moving average of $10.19. LifeVantage has a 12 month low of $5.22 and a 12 month high of $17.49. The firm has a market capitalization of $192.26 million, a PE ratio of 47.97 and a beta of 0.87.

LifeVantage (NASDAQ:LFVN) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. LifeVantage had a return on equity of 29.24% and a net margin of 2.11%. The company had revenue of $47.21 million for the quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC lifted its position in LifeVantage by 2.1% during the second quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock valued at $5,490,000 after purchasing an additional 17,300 shares during the period. Capital Management Corp VA purchased a new stake in LifeVantage during the 3rd quarter valued at $5,073,000. HighTower Advisors LLC bought a new position in shares of LifeVantage during the 3rd quarter valued at $638,000. Barclays PLC boosted its stake in shares of LifeVantage by 38.2% in the 3rd quarter. Barclays PLC now owns 41,966 shares of the company’s stock worth $507,000 after buying an additional 11,608 shares during the last quarter. Finally, Ritholtz Wealth Management grew its holdings in shares of LifeVantage by 62.0% in the third quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock worth $346,000 after acquiring an additional 10,974 shares during the period. 35.32% of the stock is owned by institutional investors.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.